title: Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer.
abstract: OBJECTIVE
  The aim of the study was to evaluate the relationship between serum carcinoembryonic antigen (CEA) kinetic and response to chemotherapy in patients with unresectable metastasis of colorectal cancer.
  
  
  METHODS
  The kinetic was calculated using the slope of an exponential-regressive curve connecting the semi-logarithmic values of CEA. Receiver operating characteristic (ROC) curves were drawn to select the CEA slope thresholds to define patients with progressive or responsive disease with the highest sensitivity, specificity, and diagnosis accuracy odds ratio (DOR). The correlation between the CEA slopes and progression-free survival (PFS) was evaluated by the Cox model and Kaplan-Meier methods.
  
  
  RESULTS
  A total of 122 patients were included. Progression defined by CEA slope greater than +0.05 resulted in sensitivity of 85.7%, specificity of 85.1%, and DOR of 34. The area under the ROC (AUROC) curve was 0.885 (95% CI, 0.815 to 0.936; P = .0001). Response defined by CEA slope less than -0.2 resulted in sensitivity of 74.7%, specificity of 82.5%, and DOR of 16. The AUROC curve was 0.847 (95% CI, 0.770 to 0.906; P = .0001). The difference between AUROC curves calculated with six or four CEA values was not significant. PFS was correlated with CEA slopes (hazard ratio, 4.6; 95% CI, 2.48 to 8.57). The median PFS was 10 months for patients with CEA slope values less than -0.2 months versus 6 months for patients with CEA slope values greater than -0.2 (P < .0001).
  
  
  CONCLUSIONS
  These results suggest that the CEA kinetic is an accurate, simple, and noninvasive method to identify the disease progression in patients with unresectable metastasis of colorectal cancer.
authors.affiliation: Hepato-Gastroenterology Department, Digestive Oncology Unit, Rouen University Hospital-Charles Nicolle-France, 1 rue de Germont, 76031 Rouen Cedex, France.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Iwanicki-Caron
authors.forename: Frédéric
authors.initials: F
authors.lastname: Di Fiore
authors.forename: Isabelle
authors.initials: I
authors.lastname: Roque
authors.forename: Emilie
authors.initials: E
authors.lastname: Astruc
authors.forename: Monica
authors.initials: M
authors.lastname: Stetiu
authors.forename: Aude
authors.initials: A
authors.lastname: Duclos
authors.forename: David
authors.initials: D
authors.lastname: Tougeron
authors.forename: Sandrine
authors.initials: S
authors.lastname: Saillard
authors.forename: Sébastien
authors.initials: S
authors.lastname: Thureau
authors.forename: Jacques
authors.initials: J
authors.lastname: Benichou
authors.forename: Bernard
authors.initials: B
authors.lastname: Paillot
authors.forename: Jean Pierre
authors.initials: JP
authors.lastname: Basuyau
authors.forename: Pierre
authors.initials: P
authors.lastname: Michel
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002272:Carcinoembryonic Antigen / Q000097:blood*; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D018450:Disease Progression; D018572:Disease-Free Survival; D016903:Drug Monitoring / Q000379:methods*; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D007700:Kinetics; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000276:immunology* / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000276:immunology* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012372:ROC Curve; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D002272:Carcinoembryonic Antigen